A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern

Simple item page
dc.contributor.authorSchultz, Barbara M.
dc.contributor.authorMelo-Gonzalez, Felipe
dc.contributor.authorDuarte, Luisa F.
dc.contributor.authorGalvez, Nicolas M. S.
dc.contributor.authorPacheco, Gaspar A.
dc.contributor.authorSoto, Jorge A.
dc.contributor.authorBerrios-Rojas, Roslye, V
dc.contributor.authorGonzalez, Liliana A.
dc.contributor.authorMoreno-Tapia, Daniela
dc.contributor.authorRivera-Perez, Daniela
dc.contributor.authorRios, Mariana
dc.contributor.authorVazquez, Yaneisi
dc.contributor.authorHoppe-Elsholz, Guillermo
dc.contributor.authorAndrade-Parra, Catalina A.
dc.contributor.authorVallejos, Omar P.
dc.contributor.authorPina-Iturbe, Alejandro
dc.contributor.authorIturriaga, Carolina
dc.contributor.authorUrzua, Marcela
dc.contributor.authorNavarrete, Maria S.
dc.contributor.authorRojas, Alvaro
dc.contributor.authorFasce, Rodrigo
dc.contributor.authorFernandez, Jorge
dc.contributor.authorMora, Judith
dc.contributor.authorRamirez, Eugenio
dc.contributor.authorGaete-Argel, Aracelly
dc.contributor.authorAcevedo, Monica
dc.contributor.authorValiente-Echeverria, Fernando
dc.contributor.authorSoto-Rifo, Ricardo
dc.contributor.authorWeiskopf, Daniela
dc.contributor.authorGrifoni, Alba
dc.contributor.authorSette, Alessandro
dc.contributor.authorZeng, Gang
dc.contributor.authorMeng, Weining
dc.contributor.authorGonzalez-Aramundiz, Jose, V
dc.contributor.authorGonzalez, Pablo A.
dc.contributor.authorAbarca, Katia
dc.contributor.authorKalergis, Alexis M.
dc.contributor.authorBueno, Susan M.
dc.date.accessioned2025-01-20T21:03:48Z
dc.date.available2025-01-20T21:03:48Z
dc.date.issued2022
dc.description.abstractCoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 and 4 weeks after two doses of CoronaVac; these levels were significantly reduced at 6 to 8 months after the two doses. Here, we report the effect of a booster dose of CoronaVac on the anti-SARS-CoV-2 immune response generated against the variants of concern (VOCs), Delta and Omicron, in adults participating in a phase III clinical trial in Chile. Volunteers immunized with two doses of CoronaVac in a 4-week interval received a booster dose of the same vaccine between 24 and 30 weeks after the second dose. Neutralization capacities and T cell activation against VOCs Delta and Omicron were assessed 4 weeks after the booster dose. We observed a significant increase in neutralizing antibodies 4 weeks after the booster dose. We also observed a rise in anti-SARS-CoV-2-specific CD4(+) T cells over time, and these cells reached a peak 4 weeks after the booster dose. Furthermore, neutralizing antibodies and SARS-CoV-2-specific T cells induced by the booster showed activity against VOCs Delta and Omicron. Our results show that a booster dose of CoronaVac increases adults' humoral and cellular anti-SARS-CoV-2 immune responses. In addition, immunity induced by a booster dose of CoronaVac is active against VOCs, suggesting adequate protection. IMPORTANCE CoronaVac is an inactivated vaccine against SARS-CoV-2 that has been approved by WHO for emergency use. Phase III clinical trials are in progress in several countries, including China, Brazil, Turkey, and Chile, and have shown safety and immunogenicity after two doses of the vaccine. This report characterizes immune responses induced by two doses of CoronaVac followed by a booster dose 5 months after the second dose in healthy Chilean adults. The data reported here show that a booster dose increased the immune responses against SARS-CoV-2, enhancing levels of neutralizing antibodies against the ancestral strain and VOCs. Similarly, anti-SARS-CoV-2 CD4(+) T cell responses were increased following the booster dose. In contrast, levels of gamma interferon secretion and T cell activation against the VOCs Delta and Omicron were not significantly different from those for the ancestral strain. Therefore, a third dose of CoronaVac in a homologous vaccination schedule improves its immunogenicity in healthy volunteers.
dc.description.abstractCoronaVac is an inactivated vaccine against SARS-CoV-2 that has been approved by WHO for emergency use. Phase III clinical trials are in progress in several countries, including China, Brazil, Turkey, and Chile, and have shown safety and immunogenicity after two doses of the vaccine.
dc.fuente.origenWOS
dc.identifier.doi10.1128/mbio.01423-22
dc.identifier.issn2150-7511
dc.identifier.urihttps://doi.org/10.1128/mbio.01423-22
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/93181
dc.identifier.wosidWOS:000839513100001
dc.issue.numero4
dc.language.isoen
dc.revistaMbio
dc.rightsacceso restringido
dc.subjectCoronaVac
dc.subjectphase III clinical trial
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectbooster dose
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleA Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
dc.typeartículo
dc.volumen13
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas